Emergent BioSolutions Inc... (EBS)
Emergent BioSolutions Statistics
Share Statistics
Emergent BioSolutions has 54.34M shares outstanding. The number of shares has increased by 3.69% in one year.
| Shares Outstanding | 54.34M |
| Shares Change (YoY) | 3.69% |
| Shares Change (QoQ) | 0.28% |
| Owned by Institutions (%) | 65.4% |
| Shares Floating | 52.97M |
| Failed to Deliver (FTD) Shares | 45 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 8.97M, so 16.51% of the outstanding shares have been sold short.
| Short Interest | 8.97M |
| Short % of Shares Out | 16.51% |
| Short % of Float | 16.68% |
| Short Ratio (days to cover) | 7.2 |
Valuation Ratios
The PE ratio is -2.66 and the forward PE ratio is 5.57. Emergent BioSolutions's PEG ratio is 0.04.
| PE Ratio | -2.66 |
| Forward PE | 5.57 |
| PS Ratio | 0.5 |
| Forward PS | 0.3 |
| PB Ratio | 1.05 |
| P/FCF Ratio | 14.15 |
| PEG Ratio | 0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Emergent BioSolutions.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.69, with a Debt / Equity ratio of 1.37.
| Current Ratio | 3.69 |
| Quick Ratio | 1.77 |
| Debt / Equity | 1.37 |
| Debt / EBITDA | 17.99 |
| Debt / FCF | 18.54 |
| Interest Coverage | -1.53 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.13M |
| Profits Per Employee | $-211.78K |
| Employee Count | 900 |
| Asset Turnover | 0.73 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 47.7M |
| Effective Tax Rate | -33.38% |
Stock Price Statistics
The stock price has increased by 126.47% in the last 52 weeks. The beta is 2.15, so Emergent BioSolutions's price volatility has been higher than the market average.
| Beta | 2.15 |
| 52-Week Price Change | 126.47% |
| 50-Day Moving Average | 6.31 |
| 200-Day Moving Average | 8.59 |
| Relative Strength Index (RSI) | 39.12 |
| Average Volume (20 Days) | 1.22M |
Income Statement
In the last 12 months, Emergent BioSolutions had revenue of 1.01B and earned -190.6M in profits. Earnings per share was -3.6.
| Revenue | 1.01B |
| Gross Profit | 1.01B |
| Operating Income | -108.7M |
| Net Income | -190.6M |
| EBITDA | 36.9M |
| EBIT | -71.9M |
| Earnings Per Share (EPS) | -3.6 |
Balance Sheet
The company has 99.5M in cash and 663.7M in debt, giving a net cash position of -564.2M.
| Cash & Cash Equivalents | 99.5M |
| Total Debt | 663.7M |
| Net Cash | -564.2M |
| Retained Earnings | -212.4M |
| Total Assets | 1.39B |
| Working Capital | 436.3M |
Cash Flow
In the last 12 months, operating cash flow was 58.7M and capital expenditures -22.9M, giving a free cash flow of 35.8M.
| Operating Cash Flow | 58.7M |
| Capital Expenditures | -22.9M |
| Free Cash Flow | 35.8M |
| FCF Per Share | 0.68 |
Margins
Gross margin is 100%, with operating and profit margins of -10.72% and -18.8%.
| Gross Margin | 100% |
| Operating Margin | -10.72% |
| Pretax Margin | -14.1% |
| Profit Margin | -18.8% |
| EBITDA Margin | 3.64% |
| EBIT Margin | -10.72% |
| FCF Margin | 3.53% |
Dividends & Yields
EBS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for EBS is $15, which is 224.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 224.7% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 0.9 |
| Piotroski F-Score | 5 |